Back to results
US 2023/0399398 A1Published application
Cd7-targeting humanized antibody and use thereof
AssigneeBioheng Therapeutics Limited
InventorsYali ZHOU, Xiaoyan JIANG, Gong CHEN, Jiangtao REN, Xiaohong He, Yanbin Wang, Lu HAN
Life of this patent
Estimating the term…
Abstract
The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.
Claims21
An anti-CD7 humanized antibody comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR-L1 as set forth in SEQ ID NO:
- 1, CDR-L2 as set forth in SEQ ID NO:
- 2 and CDR-L3 as set forth in SEQ ID NO:
- 3, the heavy chain variable region comprises CDR-H1 as set forth in SEQ ID NO:
- 4, CDR-H2 as set forth in SEQ ID NO:
- 5 and CDR-H3 as set forth in SEQ ID NO:
- 6, and the light chain variable region has at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 8, 11, 14 and 17, and the heavy chain variable region has at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs:
- 9, 12, 15 and 18.
5 more elements
(canceled)
Dependencies are inferred from the claim text.